ASP5878   Click here for help

GtoPdb Ligand ID: 11934

Synonyms: ASP-5878 | compound 27 [PMID: 35219181]
Compound class: Synthetic organic
Comment: ASP5878 is an investigational, oral pan-FGFR inhibitor that was developed for potential to combat solid tumours [1-2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 103.55
Molecular weight 407.14
XLogP 1.64
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCCn1ncc(c1)Nc1ncc(cn1)OCc1c(F)c(OC)cc(c1F)OC
Isomeric SMILES COc1cc(c(c(c1F)COc1cnc(nc1)Nc1cn(nc1)CCO)F)OC
InChI InChI=1S/C18H19F2N5O4/c1-27-14-5-15(28-2)17(20)13(16(14)19)10-29-12-7-21-18(22-8-12)24-11-6-23-25(9-11)3-4-26/h5-9,26H,3-4,10H2,1-2H3,(H,21,22,24)
InChI Key VDZZYOJYLLNBTD-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
ASP5878 was progressed to early stage clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02038673 An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors Phase 1 Interventional Astellas Pharma Inc